Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CXCL13-EcN
- Development stage
- Preclinical
- Lead developer
- Columbia University
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Intravesical
01
Overview
CXCL13-EcN is an engineered live biotherapeutic product (LBP) based on the probiotic bacterium *Escherichia coli* Nissle 1917 (EcN). It has been synthetically modified to express the human chemokine CXCL13, a key regulator of B cell recruitment and germinal center (GC) formation. In the context of bladder cancer, CXCL13-EcN is designed for intravesical administration to colonize the tumor microenvironment and stimulate the development of GCs in tumor-draining lymph nodes. This localized expression of CXCL13 aims to amplify tumor-specific antibody responses and enhance the efficacy of immune checkpoint inhibitors, such as PD-1 blockades. Preclinical studies indicate that this approach can lead to long-term survival and protective immunity against tumor rechallenge by remodeling the intratumoral microbiome and boosting adaptive humoral immunity.
- Other names
- CXCL13-expressing EcNCXCL-13-expressing EcNCXCL 13-expressing EcNengineered E. coli Nissle 1917 expressing CXCL13
02
Targets
CXCR5 (C-X-C motif chemokine receptor 5)
Beyond the preview
Go deeper on CXCL13-EcN.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CXCL13-EcN.